Kyushu University Academic Staff Educational and Research Activities Database
List of Presentations
Eiichi Ogawa Last modified date:2024.03.18

Assistant Professor / Department of Environmental Medicine and Infectious Disease / Department of Clinical Medicine / Faculty of Medical Sciences


Presentations
1. Eiichi Ogawa, Makoto Nakamuta, Motoyuki Kohjima, Toshimasa Koyanagi, Aritsune Ooho, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Takeaki Satoh, Kazuhiro Takahashi, Koichi Azuma, Rie Sugimoto, Hiromasa Amagase, Takeshi Senju, Yasunori Ichiki, Chie Morita, Masatake Tanaka, Hideyuki Nomura, Jun Hayashi, Long-term effectiveness and safety of tenofovir alafenamide for treatment-naïve and experienced patients with chronic hepatitis B: Results from a real-world, multicenter study, The Liver Meeting (AASLD) 2023, 2023.11.
2. Eiichi Ogawa, Hidenori Toyoda, Hirokazu Takahashi, Masaru Enomoto, Norifumi Kawada, Satoshi Yasuda, Keigo Kawashima, Kaori Inoue, Hiroaki Haga, Yoshiyuki Ueno, Yuichiro Eguchi, Norihiro Furusyo, Yasuhito Tanaka, Mindie H. Nguyen, Increased bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study, 第27回日本肝臓学会大会 (JDDW 2023), 2023.11.
3. Eiichi Ogawa, Makoto Nakamuta, Motoyuki Kohjima, Toshimasa Koyanagi, Aritsune Ooho, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Takeaki Satoh, Kazuhiro Takahashi, Koichi Azuma, Rie Sugimoto, Hiromasa Amagase, Takeshi Senju, Yasunori Ichiki, Chie Morita, Masatake Tanaka, Hideyuki Nomura, Jun Hayashi, Four-year safety and effectiveness of tenofovir alafenamide in treatment-experienced patients with chronic hepatitis B, APASL Oncology 2023, 2023.10.
4. Eiichi Ogawa, Latest Update of Direct-Acting Antiviral Treatment for HCV, The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023), 2023.07.
5. Eiichi Ogawa, Jung Eun Park, Vy H. Nguyen, Pei-Chien Tsai, Hidenori Toyoda, Jennifer Leong, Jennifer E. Guy, Ming-Lun Yeh, Chung-Feng Huang, Satoshi Yasuda, Hiroshi Abe, Yao-Chun Hsu, Cheng-Hao Tseng, Joanne Liu, Yao-Li Chen, Ping-Yi Lin, Dae Won Jun, Yoko Yoshimaru, Masatoshi Ishigami, Masaru Enomoto, Akihiro Tamori, Haruki Uojima, Xiao Zhong Wang, Qiang Xu, Hirokazu Takahashi, Yuichiro Eguchi, Kaori Inoue, Daniel Q. Huang, Wen Jing Zhao, Wan-Long Chuang, Chia-Yen Dai, Jee-Fu Huang, Scott Barnett, Mayumi Maeda, Ramsey Cheung, Charles Landis, Yasuhito Tanaka, Lewis R. Roberts, Myron E Schwartz, Takashi Kumada, Ming-Lung Yu, Mindie H. Nguyen, Racial and Ethnic Disparities in Direct-Acting Antiviral Treatment and Survival Outcomes for Treated/SVR and Untreated/Non-SVR Patients with Hepatitis C-Related Hepatocellular Carcinoma: A REAL-HCC Study, DDW 2023, 2023.05.
6. Eiichi Ogawa, Makoto Nakamuta, Toshimasa Koyanagi, Aritsune Ooho, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Takeaki Satoh, Kazuhiro Takahashi, Koichi Azuma, Rie Sugimoto, Hiromasa Amagase, Takeshi Senju, Yasunori Ichiki, Chie Morita, Shinji Shimoda, Hideyuki Nomura, Jun Hayashi, Virological and biochemical effectiveness of sequential nucleos(t)ide analogue treatment with tenofovir alafenamide for patients with chronic hepatitis B: 144-week results from a real-world, multicenter study, DDW 2023, 2023.05.
7. Eiichi Ogawa, Effective Antiviral Therapy in Improving the Long-Term Treatment Outcomes in Chronic Hepatitis B Patients, APASL 2023, 2023.02.
8. Eiichi Ogawa, Predictors of advanced liver disease for chronic hepatitis C patients after sustained virological response following DAA treatment, APASL 2023, 2023.02.
9. Eiichi Ogawa, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Eileen L. Yoon, Sang Bong Ahn, Son Do, Huy N. Trinh, Hirokazu Takahashi, Masaru Enomoto, Norifumi Kawada, Satoshi Yasuda, Cheng-Hao Tseng, Ming-Lun Yeh, Keigo Kawashima, Han Ah Lee, Kaori Inoue, Hiroaki Haga, Ai-Thien Do, Mayumi Maeda, Joseph H Hoang, Ramsey Cheung, Yoshiyuki Ueno, Yuichiro Eguchi, Norihiro Furusyo, Ming-Lung Yu, Yasuhito Tanaka, Mindie H. Nguyen, Increased treatment response and bone density in patients with chronic hepatitis B switched to tenofovir alafenamide from other nucleos(t)ide analogue: 96-week results from a prospective multinational study, The Liver Meeting (AASLD) 2022, 2022.11.
10. Eiichi Ogawa, Nicholas Chien, Leslie Kam, Sally Tran, Daniel Huang, Yee Hui Yeo, Fanpu Ji, Linda Henry, Ramsey Cheung, Mindie H. Nguyen, Nationwide population-level real-world evidence of long-term mortality, liver and non-liver benefits of DAA therapy in patients with chronic hepatitis treated with direct-acting antivirals, The Liver Meeting (AASLD) 2022, 2022.11.
11. Eiichi Ogawa, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Eileen L. Yoon, Sang Bong Ahn, Son Do, Huy N. Trinh, Hirokazu Takahashi, Masaru Enomoto, Satoshi Yasuda, Cheng-Hao Tseng, Ming-Lun Yeh, Keigo Kawashima, Han Ah Lee, Kaori Inoue, Hiroaki Haga, Alex Do, Mayumi Maeda, Joseph H Hoang, Ramsey Cheung, Yoshiyuki Ueno, Yuichiro Eguchi, Norihiro Furusyo, Ming-Lung Yu, Yasuhito Tanaka, Mindie H. Nguyen, Improved treatment response and bone density in patients with chronic hepatitis B switched to tenofovir alafenamide from other nucleos(t)ide analogue: 96-week results from a prospective multinational study, The International Liver Congress (EASL 2022), 2022.06.
12. Eiichi Ogawa, Makoto Nakamuta, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Aritsune Ooho, Koichi Azuma, Kazuhiro Takahashi, Takeaki Satoh, Toshimasa Koyanagi, Nobuyuki Yamashita, Yasunori Ichiki, Naoki Yamashita, Masami Kuniyoshi, Kimihiko Yanagita, Hiromasa Amagase, Chie Morita, Rie Sugimoto, Masaki Kato, Shinji Shimoda, Hideyuki Nomura, Jun Hayashi, Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by DAAs, The Liver Meeting (AASLD) 2021, 2021.11.
13. Eiichi Ogawa, Enhancing care for patients with CHB, APASL 2021, 2021.02.
14. Ogawa E, Toyoda H, Jun DW, Hsu YC, Yoon EL, Ahn SB, Yeh ML, Yasuda S, Kawashima K, Do S, Trinh HN, Takahashi H, Enomoto M, Tseng CH, Inoue K, Haga H, Maeda M, Kam L, Cheung R, Ueno Y, Eguchi Y, Furusyo N, Yu ML, anaka Y, Nguyen MH, Sequential Therapy with Tenofovir Alafenamide (TAF) in Patients with Chronic Hepatitis B (CHB): An Interim Analysis of an Ongoing Multinational Prospective Study, APASL 2021, 2021.02.
15. Eiichi Ogawa, Hidenori Toyoda, Yao-Chun Hsu, Dae Won Jun, Eileen L. Yoon, Sang Bong Ahn, Ming-Lun Yeh, Son Do, Satoshi Yasuda, Huy N. Trinh, Hirokazu Takahashi, Masaru Enomoto, Cheng-Hao Tseng, Kaori Inoue, Hiroaki Haga, Mayumi Maeda, Leslie Kam, Ramsey Cheung, Yoshiyuki Ueno, Yuichiro Eguchi, Norihiro Furusyo, Ming-Lung Yu, Yasuhito Tanaka, Mindie H. Nguyen, Sequential Therapy with Tenofovir Alafenamide in Patients with Chronic Hepatitis B: An Interim Analysis of an Ongoing Multinational, Prospective Study, The Liver Meeting (AASLD) 2020, 2020.11.
16. Eiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Aritsune Ooho, Koichi Azuma, Kazuhiro Takahashi, Takeaki Satoh, Toshimasa Koyanagi, Yasunori Ichiki, Masami Kuniyoshi, Kimihiko Yanagita, Hiromasa Amagase, Chie Morita, Rie Sugimoto, Masaki Kato, Shinji Shimoda, Jun Hayashi, Development of hepatocellular carcinoma by the older generations of patients after HCV cure by all-oral DAA therapy: Results from a large-scale, multicenter cohort study, The Liver Meeting (AASLD) 2020, 2020.11.
17. Eiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Aritsune Ooho, Koichi Azuma, Kazuhiro Takahashi, Takeaki Satoh, Toshimasa Koyanagi, Yasunori Ichiki, Masami Kuniyoshi, Kimihiko Yanagita, Hiromasa Amagase, Chie Morita, Rie Sugimoto, Masaki Kato, Shinji Shimoda, Jun Hayashi, Development of hepatocellular carcinoma by patients aged 75 years or over after HCV elimination by all-oral DAA therapy: Results from a large-scale, multicenter cohort study, The Digital International Liver Congress (EASL, Digital ILC 2020), 2020.08.
18. Eiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, Norihiro Furusyo, Toshimasa Koyanagi, Kazufumi Dohmen, Aritsune Ooho, Takeaki Satoh, Akira Kawano, Eiji Kajiwara, Kazuhiro Takahashi, Koichi Azuma, Rie Sugimoto, Hiromasa Amagase, Masami Kuniyoshi, Yasunori Ichiki, Chie Morita, Masaki Kato, Shinji Shimoda, Jun Hayashi, Clinical outcomes of chronic hepatitis B patients who switched from entecavir or tenofovir disoproxil fumarate to tenofovir alafenamide, APASL 2020, 2020.03.
19. Eiichi Ogawa, Hidenori Toyoda, Etsuko Iio, Masaru Enomoto, Shinji Iwane, Toshifumi Tada, Satoshi Yasuda, Hirokazu Takahashi, Yuichiro Eguchi, Yoshiyuki Ueno, Akihiro Tamori, Norihiro Furusyo, Yasuhito Tanaka, Mindie H. Nguyen, SVR to DAA therapy in active HCC, inactive HCC, and non-HCC HCV patients: A propensity score matched study from the Asia Liver Consortium, 第23回日本肝臓学会大会 (JDDW 2019), 2019.11.
20. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Makoto Nakamuta, Akira Kawano, Takeaki Satoh, Aritsune Ooho, Koichi Azuma, Toshimasa Koyanagi, Eiji Kajiwara, Yasunori Ichiki, Masami Kuniyoshi, Kimihiko Yanagita, Hiromasa Amagase, Chie Morita, Rie Sugimoto, Shinji Shimoda, Masaki Kato, Jun Hayashi, Incidence of hepatocellular carcinoma and mortality after HCV elimination by all-oral DAA therapy: Results from a large-scale, multicenter cohort study, 54th Annual Meeting of the European Association Study of the Liver (EASL) , 2019.04.
21. Eiichi Ogawa, Donghak Jeong, Yee Hui Yeo, Linda Henry, Sally Tran, Ramsey C. Cheung, Norihiro Furusyo, Mindie H Nguyen, Estimations of the total number of undiagnosed patients and antiviral treatment rate for chronic hepatitis B in the United States, The Liver Meeting (AASLD) 2018 , 2018.11.
22. Eiichi Ogawa, Etsuko Iio, Dae Won Jun, Chung-Feng Huang, Hiroaki Haga, Masaru Enomoto, Shinji Iwane, Dong Hyun Lee, Grace L.H. Wong, Hirokazu Takahashi, Hwai-I Yang, Chia-Yen Dai, Jee-Fu Huang, Jun Hayashi, Hideyuki Nomura, Makoto Nakamuta, Mi Jung Jun, Norihiro Furusyo, Yasuhito Tanaka, Mei-Hsuan Lee, Sally Tran, Ming-Lung Yu, Akihiro Tamori, Yoshiyuki Ueno, Yuichiro Eguchi, Linda Henry, Mindie H. Nguyen, Effectiveness and safety of DAA treatment for chronic hepatitis C patients with previous hepatocellular carcinoma: Results from a real-world, multicenter study of Asian countries, The Liver Meeting (AASLD) 2018, 2018.11.
23. Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Development of hepatocellular carcinoma after HCV eradiation following all-oral DAAs - Results from a multicenter study of KULDS -, 第22回日本肝臓学会大会 (JDDW 2018), 2018.11.
24. Eiichi Ogawa, Donghak Jeong, Yee Hui Yeo, Linda Henry, Sally Tran, Mindie H Nguyen, Estimating the number of undiagnosed patients and antiviral treatment rate for chronic hepatitis B in the United States using the Truven Health MarketScan Database, Digestive Disease Week in 2018, 2018.06.
25. Eiichi Ogawa, Donghak Jeong, Yee Hui Yeo, Mindie H Nguyen, Estimated the number of undiagnosed patients and antiviral treatment rate of chronic hepatitis B in the U.S. based on the Truven Health MarketScan Database, 53th Annual Meeting of the European Association Study of the Liver (EASL), 2018.04.
26. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Shinji Shimoda, Masaki Kato, Eiji Kajiwara, Jun Hayashi, Development of hepatocellular carcinoma following HCV eradication by direct-acting antivirals: Real-life experience from Japanese multicenter cohort, 53th Annual Meeting of the European Association Study of the Liver (EASL), 2018.04.
27. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Shinji Shimoda, Masaki Kato, Eiji Kajiwara, Jun Hayashi, Early development of hepatocellular carcinoma after hepatitis C virus eradication in interferon-free direct-acting antiviral treatment: Results from a real-life, multicenter study, The Liver Meeting 2017 (AASLD), 2017.10.
28. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Shinji Shimoda, Masaki Kato, Eiji Kajiwara, Jun Hayashi, Effectiveness and safety of sofosbuvir-based regimens for Japanese patients with HCV genotype 1b or 2 infection: Real life experience from a multicenter cohort, 52th Annual Meeting of the European Association Study of the Liver (EASL), 2017.04.
29. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Shinji Shimoda, Masaki Kato, Eiji Kajiwara, Jun Hayashi, Effectiveness of sofosbuvir-based regimens for Japanese patients with HCV genotype 1 or 2 infection: Real life experience from a multicenter cohort, The Asian Pacific Association for the Study of the Liver Single Topic Conference 2017, 2017.04.
30. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Shinji Shimoda, Masaki Kato, Eiji Kajiwara, Jun Hayashi, Effectiveness and safety of sofosbuvir plus ledipasvir for HCV genotype 1b patients with compensated cirrhosis, 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2017), 2017.02.
31. Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Naoki Yamashita, Kazufumi Dohmen, Akira Kawano, Kazuhiro Takahashi, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Effectiveness and safety of sofosbuvir and ribavirin for elderly patients with HCV genotype 2 infection, 51th Annual Meeting of the European Association Study of the Liver (EASL) , 2016.04.
32. Eiichi Ogawa, Norihiro Furusyo, Naoki Yamashita, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Efficacy of second-generation protease inhibitor-based triple therapy for HCV genotype 1b patients, The 25th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2016) , 2016.02.
33. Eiichi Ogawa, Norihiro Furusyo, Masayuki Murata, Takeo Hayashi, Motohiro Shimizu, Haru Mukae, Kazuhiro Toyoda, Taeko Hotta, Takeshi Uchiumi, Jun Hayashi, Impact of HCV kinetics differs by the type of real-time assay used to monitor triple therapy, The 25th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2016), 2016.02.
34. Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Comparative study on the effectiveness of simeprevir or telaprevir in combination with peginterferon and ribavirin for chronic HCV genotype 1b infection, 50th Annual Meeting of the European Association Study of the Liver (EASL) , 2015.04.
35. Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Impact of the low-density lipoprotein cholesterol on response to telaprevir-based triple therapy for chronic hepatitis C patients, 49th Annual Meeting of the European Association Study of the Liver (EASL) , 2014.04.
36. Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Hiroaki Ikezaki, Satoshi Hiramine, Jun Hayashi, Prediction and its management of severe anemia in chronic hepatitis C patients treated with telaprevir-based triple therapy, IDWeek 2013, 2013.10.
37. Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Impact of the viral kinetics of chronic hepatitis C patients treated with telaprevir in combination with pegylated interferon α2b and ribavirin, 48th Annual Meeting of the European Association Study of the Liver (EASL), 2013.04.